Monoclonal antibodies (mAb) enable precise targeting of pancreatic cancer, increasing the efficacy of treatments and minimizing side effects. By utilizing cutting-edge technologies and methodologies, Alfa Cytology's monoclonal antibody development service is dedicated to facilitating the creation of highly specific and effective monoclonal antibodies.
Introduction to Therapeutic Monoclonal Antibody
Therapeutic monoclonal antibodies (mAbs) are highly specific, laboratory-produced molecules engineered to mimic the immune system's ability to target and neutralize pathogens such as bacteria and viruses, and they are characterized by their ability to bind to a singular, unique epitope on an antigen, thereby enabling precise targeting of cancer cells, minimizing off-target effects, and enhancing therapeutic efficacy. These characteristics confer several advantages in cancer therapy, including the potential for reduced systemic toxicity, and the ability to be conjugated with cytotoxic agents or radionuclides to improve the delivery of these agents directly to cancer cells.
Fig. 1 Therapeutic monoclonal antibodies act on target defected cells in four different ways. (1. Kaur N, et al, 2021)
Therapeutic Monoclonal Antibody Development for Pancreatic Cancer
| Monoclonal Antibody | Company | Target | Phase |
|---|---|---|---|
| Olaratumab | Eli Lilly and Company | Platelet-Derived Growth Factor Receptor Alpha (PDGFRα) | Phase I/II |
| Ipilimumab | Bristol Myers Squibb | CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein 4) | Phase II |
| Pembrolizumab | Merck & Co. | Programmed Death-1 (PD-1) receptor | Phase II |
| Nivolumab | Bristol Myers Squibb | Programmed Death-1 (PD-1) receptor | Phase I/II |
| Amatuximab | Morphotek, Inc. | Mesothelin | Preclinical to Phase I |
| Zolbetuximab | Astellas Pharma Inc. | Claudin 18.2 | Phase I/II |
| Magrolimab | Gilead Sciences, Inc. | CD47 | Preclinical to Phase I |
Our Services
Alfa Cytology's one-stop service offers a comprehensive solution covering all aspects of monoclonal antibody creation, providing a streamlined pathway for the generation of therapeutic antibodies targeting pancreatic cancer. Our experienced research team can provide flexible and scalable services to meet the specific needs of our clients at every stage of their projects.
Monoclonal Antibody Discovery Service
- Hybridoma Technology: Generation of hybridoma cell lines for the production of monoclonal antibodies through the fusion of B cells with myeloma cells.
- Phage Display Technology: Utilization of phage display libraries to screen and identify antibodies with high specificity and affinity for target antigens.
- Single B Cell Screening Technology: Isolation and screening of single B cells to obtain antibodies with desired characteristics directly from immunized animals.
- High-throughput Screening Technology: Implementation of high-throughput screening assays to rapidly identify potential antibody candidates from large libraries.
Monoclonal Antibody Optimization Service
Our services focus on improving various properties of antibodies to maximize their efficacy and safety.
Affinity Maturation
Techniques to increase the binding affinity of antibodies to their target antigens, improving therapeutic efficacy.
Humanization
Conversion of murine or other non-human antibodies to human or humanized versions to reduce immunogenicity and enhance compatibility.
Isotype Switching
Modification of antibody isotypes to optimize effector functions and therapeutic activity.
Fc Engineering
Engineering of the Fc region to enhance antibody-dependent cellular cytotoxicity (ADCC) and other effector functions.
Stability Enhancement
Strategies to increase the thermal and chemical stability of antibodies, ensuring long-term efficacy and shelf life.
Monoclonal Antibody Purification Service
Our antibody purification services ensure that the final product meets stringent purity and quality standards.
- Protein A/G Purification
- Ion Exchange Chromatography
- Size Exclusion Chromatography
- Endotoxin Removal
- Polishing Steps
Preclinical Research Services
These services are designed to assess the efficacy, safety, and pharmacokinetics of antibody candidates:
- In Vitro Binding Assays
- Cell-based Functional Assays
Our therapeutic monoclonal antibody development services provided represent a comprehensive and integrated approach to advancing pancreatic cancer therapies. By offering cutting-edge technologies and expert-driven processes, Alfa Cytology ensures the highest quality of antibody development, from antigen preparation to preclinical validation. For more information on these services or to initiate a collaboration, please contact us.
References
- Kaur N, Chaudhary V. Biotherapeutics and its applications in Microbiology. Environment Conservation Journal. 2021, 22(SE): 63-78.
- Huang ZQ, Buchsbaum DJ. Monoclonal antibodies in the treatment of pancreatic cancer. Immunotherapy. 2009,1(2):223-9.
